24. Xenleta

Xenleta (lefamulin)

Active ingredient: lefamulin
Disease: community-acquired bacterial pneumonia
Peak sales estimate: n/a
Approved: Aug. 19, 2019
Company: Nabriva Therapeutics

The scoop: With antibiotic-resistant bacteria on the rise, healthcare providers are looking for novel solutions from drugmakers. In August, Nabriva stepped up to the plate with FDA approval for its Xenleta, a novel antibiotic to treat community-acquired bacterial pneumonia (CABP). Xenleta is the first in a new class of antibiotics called pleuromutilins, which target a different protein synthesis binding site than older competitors. Nabriva marketed Xenleta, approved in both an oral and intravenous formulation, as a new answer for CABP, which affects around 5 million Americans each year, the Irish drugmaker said. The drug’s approval followed the second of two phase 3 trials that hit its primary endpoint in May 2018. Nabriva’s second trial compared an oral, five-day Xenleta regimen to seven days of treatment with approved antibiotic moxifloxacin in patients with moderate CABP. The trial associated the regimens with identical early clinical response rates of 90.8%, resulting in it hitting its noninferiority primary endpoint. –– Kyle Blankenship

24. Xenleta

Suggested Articles

The data was highly anticipated, especially since the two partners continued testing after the compound missed its endpoints in phase 2 studies.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Vertex is keeping mum on exact details but, as with the rest of its biopharma peers, is seeing trial disruption due to the COVID-19 pandemic.